REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study

Status unconfirmed · Phase 3

Conditions studied: HIV

In brief

The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load changes in the Remune + Amplivax group vs the Amplivax placebo groups. Additional objectives include changes in WBC White Blood Cell counts \& CD4+ \& CD8+ T cell counts along with increased HIV immunity.

Key facts

Study ID

NCT02366026

Run by

Immune Response BioPharma, Inc.

People needed

500

Starts

2017-06-01

Expected to finish

2019-06-01

Last updated by the study team

2016-02-23

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are HIV-positive and started anti-HIV drugs soon after tests showed the presence of HIV.
• Are at least 16 years old (consent of parent or guardian required if under 18 years).

You may not qualify if…

• Healthy Subjects
• Currently abuse alcohol or drugs.

Where it is running

• Clinical Site TBA — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.